Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Tumani

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Neurology|June 16, 2005
Reversible impaired memory induced by pulsed methylprednisolone in patients with MSI Uttner, S Müller, C Zinser, et al.
European Journal of Neurology|April 16, 2013
Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosisN M Roth, S Saidha, H Zimmermann, et al.
Neuroscience Letters|April 23, 2009
CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosisH Tumani, V Lehmensiek, D Rau, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 14, 2008
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis opticaS Jarius, D Franciotta, R Bergamaschi, et al.
Neurological Research and Practice|December 16, 2020
Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel diseaseA Abdelhak, A Huss, A Brück, et al.
Journal of Neuroinflammation|March 21, 2018
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literatureS Jarius, K Ruprecht, J P Stellmann, et al.
Neurology|February 11, 2012
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer diseaseM Watabe-Rudolph, Z Song, L Lausser, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2012
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapyA Harrer, H Tumani, S Niendorf, et al.
Der Nervenarzt|August 14, 2015
[Current aspects of therapy conversion for multiple sclerosis]P Kolber, F Luessi, S G Meuth, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Neurology|June 16, 2005
Reversible impaired memory induced by pulsed methylprednisolone in patients with MSI Uttner, S Müller, C Zinser, et al.
European Journal of Neurology|April 16, 2013
Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosisN M Roth, S Saidha, H Zimmermann, et al.
Neuroscience Letters|April 23, 2009
CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosisH Tumani, V Lehmensiek, D Rau, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 14, 2008
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis opticaS Jarius, D Franciotta, R Bergamaschi, et al.
Neurological Research and Practice|December 16, 2020
Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel diseaseA Abdelhak, A Huss, A Brück, et al.
Journal of Neuroinflammation|March 21, 2018
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literatureS Jarius, K Ruprecht, J P Stellmann, et al.
Neurology|February 11, 2012
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer diseaseM Watabe-Rudolph, Z Song, L Lausser, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2012
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapyA Harrer, H Tumani, S Niendorf, et al.
Der Nervenarzt|August 14, 2015
[Current aspects of therapy conversion for multiple sclerosis]P Kolber, F Luessi, S G Meuth, et al.
Pageof 8